Lives unaffected by cystic fibrosis

Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • Restore CFTR FunctionClosed to enrollment Location: Multicentre

    A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis Harbouring One F508del CFTR Mutation and a Second Gating (Class III) Mutation , protocol number NCT03045523 GLPG2222-CL-201

    This clinical study is a phase IIa, multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate two doses of orally administered GLPG2222 in adult subjects with a confirmed diagnosis of CF harbouring one F508del CFTR mutation and a second gating (class III) mutation and on stable treatment with ivacaftor. Up to 35 evaluable subjects are planned to be included in the study. Eligible subjects must be on stable treatment with physician prescribed ivacaftor (Kalydeco®) for at least 28 days at the baseline visit. They will be randomized in a 2:2:1 ratio to receive one of two active doses of GLPG2222 (150 mg q.d. or 300 mg q.d.) or placebo q.d. administered for 29 days. Subjects will be in the study for a minimum of 6 weeks and a maximum of 10 weeks, from screening until the follow-up visit.

    • Age:

      18 years and older

    • Mutation(s):

      One F508del mutation on one allele in the CFTR gene, a gating (class III) mutation (one of the following: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R) on the 2nd allele in the

    • FEV1% Predicted:

      (FEV1) ≥ 40% of predicted normal for age, gender and height at screening

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • ObservationalEnrolling Location: Multiple US sites

    PREDICT: NTM observational study (NTM-OB-17) , protocol number NCT02073409 NTM-OB-17

    This study is taking place at multiple care centers across the U.S. It will evaluate the current standard of diagnosing nontuberculous mycobacteria (NTM) in people with CF.

    • Age:

      10 years and older

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      No FEV1 limit

    • Number of Visits:

      20

    • Length of Participation:

      5 Years

    Contact us about this clinical Trial >
  • Restore CFTR FunctionRecruiting Location: Multiple care centres across the US & Australia

    Phase 3 study of long-term ivacaftor in babies who have a CFTR gating mutation , protocol number VX-770-126 NCT03277196

    This is a Phase-3, 2-arm, multicentre study with an open-label ivacaftor arm and an observational arm to evaluate the safety and efficacy of long-term ivacaftor treatment in subjects with cystic fibrosis (CF) who are less than 24 months of age at treatment initiation and have approved Ivacaftor-Responsive mutation

    • Age:

      0 days to 24 months

    • Mutation(s):

      One copy F508del or no copies F508del

    • FEV1% Predicted:

      No FEV1 limit

    • Number of Visits:

      18

    • Length of Participation:

      128 weeks

    Contact us about this clinical Trial >
  • Anti-InflammatoryClosed to enrollment Location: Multiple care centres across the US

    Phase 2 study of JBT-101 in people with CF , protocol number Corbus JBT101-CF-002 NCT03451045

    This study evaluated the safety and effectiveness of the anti-inflammatory drug JBT-101 (lenabasum), as well as how the body processes the drug, in adults with CF.

    • Age:

      12 years and older

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      40-100%

    • Number of Visits:

      10

    • Length of Participation:

      32 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: Multiple care centres across the US

    Phase 2a study of Galapagos GLPG2222 in adults with CF , protocol number NCT03119649 Galapagos GLPG2222-CL-202

    This study evaluated the safety and effectiveness of the CFTR modulator GLPG2222. This study was for people with CF who have two copies of the F508del mutation.

    • Age:

      18 years and older

    • Mutation(s):

      Two copies of F508del

    • FEV1% Predicted:

      40% or greater

    • Number of Visits:

      5

    • Length of Participation:

      10 weeks

    Contact us about this clinical Trial >
  • ObservationalEnrolling Location: Multiple US sites

    Rare Mutation Cell Collection (RARE) , protocol number NCT 03161808 NCT 03161808

    This study is taking place at multiple care centres across the US. Researchers will collect and make available for study cells from people with rare CFTR mutations.

    • Age:

      2 years and older

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      40-90%

    • Number of Visits:

      8

    • Length of Participation:

      30 days

    Contact us about this clinical Trial >
  • Restore CFTR FunctionClosed to enrollment Location: USA, Australia, Europe

    Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor , protocol number NCT02549451 VX15-809-110

    Study 110 is a Phase 3, multicenter study in subjects aged 6 years and older with cystic fibrosis (CF) who are homozygous for the F508del-CF transmembrane conductance regulator (CFTR) mutation and who participated in Study 109 (NCT02514473) or Study 011B (NCT01897233). Study 110 is designed to evaluate the safety and efficacy of long term treatment of lumacaftor in combination with ivacaftor.

    • Age:

      6-11 years and 12 years and older

    • Mutation(s):

      Homozygous for the F508del-CFTR Mutation

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Mucociliary ClearanceCompleted with results Location: Multiple care centres across the US

    Phase 1b study of inhaled AZD5634 in adults with CF , protocol number AZD5634 NCT02950805

    This study evaluated the safety and tolerability of the inhaled drug AZD5634 in people with CF. It also evaluated the effect of AZD5634 on improving the ability to clear mucus from the lungs (lung mucociliary clearance - MCC).

    • Age:

      18 - 60 years

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      40% or greater

    • Number of Visits:

      4

    • Length of Participation:

      4 months

    Contact us about this clinical Trial >
  • Anti-InfectiveCompleted with results Location: Multiple care centres across the US

    Phase 3 study of inhaled vancomycin in adults and children 6 years and older with cystic fibrosis. , protocol number SAVARA SAV005 NCT03181932

    This study evaluated the effectiveness of the inhaled drug vancomycin hydrochloride inhalation powder (AeroVanc) in adults and children 6 years and older with CF and positive cultures for methicillin-resistant Staphylococcus aureus (MRSA).

    • Age:

      6 years and older

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      30-100%

    • Number of Visits:

      8

    • Length of Participation:

      12 months

    Contact us about this clinical Trial >
  • Restore CFTR FunctionClosed to enrollment Location: Multicentre

    A Phase 3 Study of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor , protocol number NCT02412111 VX14-661-109

    This is a Phase 3, randomized, double-blind, ivacaftor-controlled, parallel-group, multicenter study in subjects aged 12 years and older with CF who are heterozygous for the F508del-CFTR mutation and a second CFTR allele with a gating defect that is clinically demonstrated to be ivacaftor responsive.

    • Age:

      12 years and older

    • Mutation(s):

      Heterozygous for F508del-CFTR mutation and a second CFTR allele with a gating defect that is clinically demonstrated to be ivacaftor responsive

    • FEV1% Predicted:

      FEV1 ≥40% and ≤90% of predicted normal for age, sex, and height

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Displaying results 131-140 (of 214)
     |<  <  10 - 11 - 12 - 13 - 14 - 15 - 16 - 17 - 18 - 19  >  >|